A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors AbbVie
- 28 Jun 2017 Planned End Date changed from 25 Nov 2021 to 1 Nov 2020.
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.